← Back to Search

NMDA Receptor Antagonist

Ketamine for Depression

Phase 1
Waitlist Available
Research Sponsored by Massachusetts General Hospital
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Satisfy criteria for Major Depression Disorder (MDD) according to DSM-5
No contraindication to KET treatment such as KET allergy or uncontrolled hypertension
Must not have
History of receiving electroconvulsive therapy in the past 1 year
No serious medical or neurological illness, including previously known HIV positive status
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
No Placebo-Only Group

Summary

This trial aims to understand how ketamine works to rapidly improve depression by examining its effects on gene expression pathways in neurons. By studying the brain's connections and molecular targets, the researchers hope to develop better

Who is the study for?
This trial is for individuals experiencing depression, self-harm tendencies, or suicidal thoughts. Specific eligibility criteria are not provided but typically include factors like age range, severity of symptoms, and absence of certain medical conditions.
What is being tested?
The study investigates how a low dose of ketamine given through an IV can quickly relieve depression and prevent suicide. It looks at changes in genes within neurons from the nose and links them to brain connectivity improvements observed via imaging techniques.
What are the potential side effects?
While specific side effects are not listed here, common ones associated with ketamine may include dizziness, blurred vision, nausea, euphoria, disorientation or confusion shortly after administration.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have been diagnosed with Major Depression Disorder.
Select...
I am not allergic to KET and my blood pressure is under control.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have not had electroconvulsive therapy in the last year.
Select...
I do not have any serious illnesses or HIV.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Intravenous KetamineExperimental Treatment1 Intervention
Intravenous ketamine will be given at a dose of 0.5 mg/kg over 40 minutes with a maximum dose of 60 mg.

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

Massachusetts General HospitalLead Sponsor
3,023 Previous Clinical Trials
13,317,829 Total Patients Enrolled
192 Trials studying Depression
33,942 Patients Enrolled for Depression
~80 spots leftby Jun 2030
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top